While MedWatch is a valuable tool, it has certain limitations. One major limitation is the underreporting of adverse events, which can lead to an incomplete understanding of the true incidence and impact of these events. Additionally, the quality of the data can vary, as reports are often submitted voluntarily and may lack detailed information. Despite these limitations, MedWatch remains a critical component of the broader pharmacovigilance system.
